What liver tests (LFTs) are typically monitored with tigecycline?
With tigecycline, clinicians commonly monitor liver-related labs used as “LFTs,” such as:
- Serum ALT (alanine aminotransferase)
- Serum AST (aspartate aminotransferase)
- Alkaline phosphatase
- Total bilirubin
- Sometimes albumin and INR are followed if there are signs of worsening liver function
The goal is to detect drug-associated liver injury early, since tigecycline can be linked to abnormal liver enzymes and cholestatic or mixed patterns of injury in some patients.
How often should LFTs be checked during tigecycline treatment?
There is no single universal schedule for every patient, but typical practice is based on risk and how long therapy lasts:
- Baseline LFTs before starting tigecycline
- Repeat LFTs during therapy if liver tests are elevated at baseline, if treatment is prolonged, or if the patient develops symptoms suggestive of liver injury (for example, jaundice, dark urine, right upper-quadrant pain, unexplained fatigue, or worsening nausea)
- More frequent monitoring in patients with pre-existing liver disease, those receiving other hepatotoxic drugs, or those who are critically ill
When should tigecycline be held or stopped due to elevated LFTs?
Decisions are usually based on both the lab magnitude and whether the patient has liver-related symptoms. Clinicians generally pay close attention to:
- Rising ALT/AST with or without bilirubin elevation
- Any bilirubin increase, especially if accompanied by enzyme elevations
- Development of clinical signs of hepatitis or cholestasis
If LFT abnormalities worsen or if bilirubin increases (suggesting more clinically significant injury), tigecycline is often reassessed and may be discontinued depending on severity and alternative options.
What liver injury pattern is seen with tigecycline?
Reported liver effects with tigecycline include abnormal transaminases and, in some cases, cholestatic or mixed liver injury patterns (enzyme elevations with variable bilirubin changes). Monitoring focuses on tracking both enzyme trends and bilirubin to separate mild, reversible lab changes from clinically meaningful injury.
Does tigecycline dosing change with liver impairment?
Dosing adjustments and recommendations depend on the specific prescribing information and the degree of hepatic impairment. In general, clinicians assess severity of liver dysfunction and monitor closely when hepatic impairment is present because drug exposure can be altered.
What patient questions come up about “LFT monitoring” with tigecycline?
Patients and families often ask:
- Why blood tests are needed while on tigecycline (to detect liver irritation early)
- What symptoms should trigger urgent contact (jaundice, dark urine, severe abdominal pain, marked fatigue)
- Whether abnormal results are expected or dangerous (mild elevations can occur, but worsening or bilirubin rise is taken more seriously)
If you share the dosing context (e.g., inpatient duration, baseline liver history, current AST/ALT/bilirubin values), I can map the typical monitoring approach to that scenario.